The biotech said the money will be used in part to move one of its potential therapies for diabetic kidney disease to a Phase 2 clinical trial later this year. (The Logic)
Skip to content
The biotech said the money will be used in part to move one of its potential therapies for diabetic kidney disease to a Phase 2 clinical trial later this year. (The Logic)
Talking point: Inversago, which focuses on developing treatments for metabolic diseases, will also use the funds raised to accelerate other possible therapies that are in preclinical development. New Enterprise Associates led the round, which also saw participation from new investors Forbion Growth and Amgen Ventures, as well as existing investors including Fonds de solidarité FTQ. Inversago has previously raised a $47-million Series B and $7-million Series A.
Loading...
Thanks for sharing!
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseThis account has reached its share limit.
If you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseGift the full article!
You have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Most Popular This Week
In-depth, agenda-setting reporting
Great journalism delivered straight to your inbox.
Analysis
The ‘red line’ in U.S. trade talks that sets Canada apart from other countries
Briefing
Canadian inflation remains in the BoC’s comfort zone, barely
Cohere in talks to raise as much as US$3B: Report
Stellantis agrees to sell Ontario factory to armoured-vehicle maker Roshel
Best business newsletter in Canada
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
Exclusive events
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership in The Logic Council
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.
